Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 17/20 | 0.46 |
| ▸ | AKT1S1 | Q96B36 | 2/20 | 0.39 |
| ▸ | AKT3 | Q9Y243 | 6/20 | 0.39 |
| ▸ | AKT2 | P31751 | 5/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727946 | 0.93 | AKT1 (0.41) | AKT1AKT1S1AKT3AKT2CYP3A4 | |
| SCHEMBL3727949 | 0.93 | AKT1 (0.41) | AKT1AKT1S1AKT3AKT2CYP3A4 | |
| SCHEMBL3726648 | 0.92 | AKT1 (0.46) | AKT1AKT1S1AKT3AKT2KIT | |
| SCHEMBL3726646 | 0.92 | AKT1 (0.46) | AKT1AKT1S1AKT3AKT2KIT | |
| SCHEMBL15918096 | 0.88 | AKT1 (0.43) | AKT1AKT1S1AKT3AKT2KIT | |
| SCHEMBL3723912 | 0.86 | AKT3 (0.49) | AKT1AKT3AKT2CYP3A4 | |
| SCHEMBL3723911 | 0.86 | AKT3 (0.49) | AKT1AKT3AKT2CYP3A4 | |
| SCHEMBL27800354 | 0.85 | AKT1 (0.46) | AKT1AKT1S1AKT3AKT2KIT | |
| SCHEMBL3727980 | 0.84 | AKT1 (0.43) | AKT1AKT1S1AKT3AKT2 | |
| SCHEMBL3726940 | 0.83 | AKT1 (0.43) | AKT1AKT1S1AKT3AKT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841304-B2 | Pyrrolopyridines as kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| EP-2242755-B1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-2242755-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009089352-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324041-A1 | PYRROLOPYRIDINES AS KINASE INHIBITORS | CHEK2, CHEK1, BUB1B | AKT1 531/4885AKT1S1 562/4885AKT3 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.